FZ AD004
Alternative Names: FZ-AD004; FZ-AD004 ADC; FZ-AD004 antibody drug conjugate; FZAD004-BB05Latest Information Update: 25 Aug 2023
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Jun 2023 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT05914545)
- 18 Jan 2023 Preclinical trials in Solid tumours in China, before January 2023 (IV)
- 18 Jan 2023 NMPA accepts IND application for FZ AD004 in Solid tumours